Metabotropic glutamate receptor group I (Group I mGluR)

Metabotropic glutamate receptor group I refers collectively to two closely related G protein-coupled receptors—mGluR1 and mGluR5—that bind the neurotransmitter glutamate but do not form ion channels themselves. Instead, they modulate neuronal excitability through second messenger systems after coupling primarily with Gαq proteins. Activation leads to stimulation of phospholipase Cβ1 with production of diacylglycerol and IP3—resulting in increased intracellular calcium levels—and subsequent activation of protein kinase C along with other downstream kinases such as ERK/MAPK/AKT involved in cell growth/survival/differentiation pathways[3][4]. Group I metabotropic glutamate receptors are predominantly located postsynaptically throughout the central nervous system where they regulate synaptic transmission strength (“synaptic plasticity”), influence learning/memory processes via long-term potentiation/depression mechanisms,[7] interact functionally with NMDA-type ionotropic glutamate receptors,[5] modulate gene expression,[6] affect dopaminergic/adrenergic neurotransmission,[5] and play key roles both under physiological conditions (such as memory formation) and pathological states including neurodegeneration (Alzheimer’s/Parkinson’s/Huntington’s), epilepsy/seizures,[4] fragile X syndrome,[6] schizophrenia/anxiety/OCD/depression,[4][6], drug addiction,[4], cancer/glioma progression.[2] Therapeutically relevant drugs target these receptors either directly at their orthosteric site or via allosteric modulation—with negative allosteric modulators showing promise particularly against neurological/psychiatric diseases associated with excessive excitation or maladaptive synaptic changes.[1][2] No evidence suggests that "Metabotropic glutamate receptor group I" is an incorrect term—it is a standard classification encompassing both mGluR1 (“metabotropic glutamate receptor 1”) and mGluR5 (“metabotropic glutamate receptor 5”).

Other names

Group I metabotropic glutamate receptormGluR1/5mGluR1 and mGluR5 receptorsGroup I mGluRs

Drugs targeting group I metabotropic glutamate receptors typically act as agonists or antagonists/allosteric modulators to modulate the activity of these GPCRs. Negative allosteric modulators inhibit receptor signaling by binding to sites distinct from the orthosteric ligand-binding site; agonists activate the receptor by mimicking glutamate binding; antagonists block activation by endogenous ligands. These actions can alter downstream signaling pathways such as phospholipase C activation and subsequent intracellular calcium release or PKC activation[1][4].